Ameriprise
CPRX

Ameriprise’s Catalyst Pharmaceutical CPRX Stock Holding History

Ameriprise’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.51M Sell
238,981
-10,324
-4% -$305K ﹤0.01% 2261
2026
Q1 		$6.17M Buy
249,305
+33,383
+15% +$795K ﹤0.01% 2301
2025
Q4 		$5.04M Sell
215,922
-26,800
-11% -$597K ﹤0.01% 2430
2025
Q3 		$4.78M Sell
242,722
-7,427
-3% -$153K ﹤0.01% 2483
2025
Q2 		$5.43M Sell
250,149
-19,029
-7% -$449K ﹤0.01% 2293
2025
Q1 		$6.53M Sell
269,178
-13,656
-5% -$308K ﹤0.01% 2103
2024
Q4 		$5.9M Buy
282,834
+5,177
+2% +$111K ﹤0.01% 2247
2024
Q3 		$5.52M Sell
277,657
-39,318
-12% -$729K ﹤0.01% 2305
2024
Q2 		$4.91M Sell
316,975
-64,375
-17% -$1M ﹤0.01% 2329
2024
Q1 		$6.08M Sell
381,350
-70,885
-16% -$1.07M ﹤0.01% 2213
2023
Q4 		$7.6M Buy
452,235
+35,476
+9% +$485K ﹤0.01% 2017
2023
Q3 		$4.87M Sell
416,759
-20,209
-5% -$270K ﹤0.01% 2311
2023
Q2 		$5.87M Sell
436,968
-18,271
-4% -$263K ﹤0.01% 2219
2023
Q1 		$7.55M Sell
455,239
-181,502
-29% -$2.99M ﹤0.01% 1999
2022
Q4 		$11.8M Buy
636,741
+14,386
+2% +$221K ﹤0.01% 1605
2022
Q3 		$7.99M Buy
622,355
+414,034
+199% +$4.91M ﹤0.01% 1871
2022
Q2 		$1.46M Buy
208,321
+11,241
+6% +$82.4K ﹤0.01% 2952
2022
Q1 		$1.63M Sell
197,080
-341,779
-63% -$2.42M ﹤0.01% 3002
2021
Q4 		$3.65M Buy
538,859
+477,832
+783% +$3.14M ﹤0.01% 2679
2021
Q3 		$324K Buy
+61,027
New +$334K ﹤0.01% 3536
2021
Q2 		– Sell
-10,955
Closed -$50K – 3903
2021
Q1 		$50K Hold
10,955
– – ﹤0.01% 3801
2020
Q4 		$37K Sell
10,955
-17,911
-62% -$60.2K ﹤0.01% 3732
2020
Q3 		$86K Buy
28,866
+2,074
+8% +$8.11K ﹤0.01% 3652
2020
Q2 		$124K Buy
+26,792
New +$120K ﹤0.01% 3562
2018
Q1 		– Sell
-341,956
Closed -$1.34M – 3633
2017
Q4 		$1.34M Buy
+341,956
New +$1.13M ﹤0.01% 2851

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise's CPRX Position: Q2 2026 in Review

Ameriprise reduced its Catalyst Pharmaceutical (CPRX) stake by 4.1% in Q2 2026, selling an estimated $305K and leaving 238,981 shares worth $7.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2261.

Ameriprise first reported a position in CPRX in Q4 2017 and has held it in 25 quarters since. The position peaked at $11.8M in Q4 2022. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Ameriprise held 238,981 shares of Catalyst Pharmaceutical worth $7.51M as of Q2 2026.
  • Ameriprise sold 10,324 Catalyst Pharmaceutical shares in Q2 2026, an estimated $305K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2261 holding.
  • Ameriprise first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 25 quarters since.
  • Ameriprise's Catalyst Pharmaceutical position peaked at $11.8M in Q4 2022.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.